Half-year report · Q2
4483.TEDINET S100UQ55
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥19.2bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥32.4bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥13.7bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥6.9bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥2.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥4.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥2.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥2.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥2.7bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥136.1bn | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥122.5bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥100.0bn | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥63.7bn | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥51.8bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥72.4bn | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥70.7bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥68.7bn | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥64.5bn | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥72.1bn | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥70.6bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥68.6bn | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥27.5bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥14.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥21.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥22.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥10.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | −¥17m | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥2.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥4.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥24.9bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥3.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | ¥6.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥16.6bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥341m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥33.51 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.76 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥42.2 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥33.18 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥69.95 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥40.53 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 52.9% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 57.6% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.6% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥21m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥21m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥379m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥649m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥649m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥116m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥21m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.1bn |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥19.2bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥19.2bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥21m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥5.0bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥89m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥89m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥338m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥50m |
| jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥133m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥9.8bn |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥38m |
| jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E35308-000Tele Medicinereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.0bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥13.7bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥89m |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥3.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 769
| Item | Context | Value | Unit |
|---|---|---|---|
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所(プライム市場) | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Text · Plus | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)オムロン株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No1MajorShareholdersMember | Original text (Japanese)京都府京都市下京区塩小路通堀川東入南不動堂町801番地 | |
| Name major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)日本マスタートラスト信託銀行株式会社(信託口) | |
| Address major shareholders | CurrentQuarterInstant_No2MajorShareholdersMember | Original text (Japanese)東京都港区赤坂一丁目8番1号 | |
| Name major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)ノーリツ鋼機株式会社 | |
| Address major shareholders | CurrentQuarterInstant_No3MajorShareholdersMember | Original text (Japanese)東京都港区麻布十番一丁目10番10号 | |
| Name major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)株式会社日本カストディ銀行(信託口) | |
| Address major shareholders | CurrentQuarterInstant_No4MajorShareholdersMember | Original text (Japanese)東京都中央区晴海一丁目8番12号 | |
| Name major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)松島 陽介 | |
| Address major shareholders | CurrentQuarterInstant_No5MajorShareholdersMember | Original text (Japanese)東京都港区 | |
| Name major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No6MajorShareholdersMember | Original text (Japanese)56,GRAND RUE L-1660 LUXEMBOURG (東京都千代田区丸の内一丁目4番5号 決済事業部) | |
| Name major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)山元 雄太 | |
| Address major shareholders | CurrentQuarterInstant_No7MajorShareholdersMember | Original text (Japanese)東京都港区 | |
| Name major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No8MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No9MajorShareholdersMember | Text · Plus | |
| Name major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Text · Plus | |
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsTreasurySharesEtcMember | - | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式であります。なお、単元株式数は100株であります。 | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesLessThanOneUnitMember | - | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)株式会社JMDC | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都港区芝大門二丁目5番5号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYTDDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of financial position IFRS (text) | CurrentYTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |